Why the study?
Clinical trials evaluate nivolumab in selected patient populations, leaving its efficacy and safety in advanced melanoma under real-life conditions to be analyzed.
Does nivolumab improve overall survival and progression-free survival in patients with advanced melanoma under real-life conditions?
Does nivolumab improve overall survival and progression-free survival in patients with advanced melanoma under real-life conditions?
Answers are grounded in this paper and cite their sources.
Under real-life conditions, nivolumab demonstrated efficacy and safety in advanced melanoma consistent with clinical trial data, with a median PFS of 13 months.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Samaran et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: